DMT310-009 Topical in the Treatment of Acne Vulgaris

Description

The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris

Conditions

Acne Vulgaris

Talk to us

Study Overview

On this page

Study Details

Study overview

The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris

A PHASE 3 STUDY OF TOLERABILITY, SAFETY, AND EFFICACY, OF DMT310 IN PATIENTS WITH ACNE VULGARIS

DMT310-009 Topical in the Treatment of Acne Vulgaris

Condition
Acne Vulgaris
Intervention / Treatment

-

Contacts and Locations

Fremont

Center for Dermatology Clinical Research, Inc., Fremont, California, United States, 94538

Austin

DermResearch, Austin, Texas, United States, 78759

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patient sex at birth, male or non-pregnant female at least 9 years of age
  • * Clinical diagnosis of moderate to severe acne vulgaris as determined by:
  • * Patient is willing to apply the Investigational Product as directed
  • * Patient is willing and able to comply with the protocol
  • * Patient is pregnant or planning to become pregnant
  • * Patient is taking a topical therapy on the face which may affect the patient's acne

Ages Eligible for Study

9 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Dermata Therapeutics,

Study Record Dates

2025-03-30